INTERVIEW: DPx's Jim Mullen delivers the $2.6bn message
This article was originally published in Scrip
The recent merger of Patheon and DPP makes the company one of the largest outsourcing players in the market. CEO Jim Mullen explains why the company now has to live up to the hype.
You may also be interested in...
Podcast: Diversity, Equity, and Inclusion Measures Continue to Evolve in the Clinical Space
Listen to expert perspectives from Tracey Parker, Vice President, Biometrics, Advanced Clinical and Rebecca Starkie, Senior Global Patient Engagement Director, Advanced Clinical on the recent history of DEI in clinical trials and the barriers to patient participation. Examine the key drivers that have influenced the development of diversity, equity, and inclusion programs for clinical trials.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
Eisai/Biogen’s Leqembi Breezes Through Adcomm; Labeling Discussions With US FDA May Be Knottier
To get regular approval, the Alzheimer’s treatment could see tightened labeling on the need to test for ApoE ε4 status given advisory committee recommendations. Some panelists also raised concerns around use with anticoagulants and in patients with cerebral amyloid angiopathy.